Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Weleader Biomedical CoROCO:7713 69 EV-to-EBIT is 12.78 as of Sep. 11, 2026, which is 21% below its 10-year median of 16.15. GuruFocus rates ROCO:7713 with a GF Score™ of 69/100 and a GF Value™ of NT$74.30 (Fairly Valued). The stock has 5 warning signs investors should review. Among 475 Medical Devices & Instruments companies, Weleader Biomedical Co ranks better than 64.84% on this metric.
The historical rank and industry rank for Weleader Biomedical Co's EV-to-EBIT or its related term are showing as below:
ROCO:7713'
s EV-to-EBIT Range Over the Past 10 Years
Min: 12.31 Med: 16.15 Max: 35.91
Current: 12.78
During the past 6 years, the highest EV-to-EBIT of Weleader Biomedical Co was 35.91. The lowest was 12.31. And the median was 16.15.
ROCO:7713's EV-to-EBIT is ranked better than 64.84% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 18.21
vs ROCO:7713: 12.78
Weleader Biomedical Co (ROCO:7713) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Weleader Biomedical Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$4,020 Mil.
Weleader Biomedical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$324 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Weleader Biomedical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Weleader Biomedical Co EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Weleader Biomedical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Weleader Biomedical Co's EV-to-EBIT falls into.
Weleader Biomedical Co's current Enterprise Value is NT$4,143 Mil.
Weleader Biomedical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$324 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Weleader Biomedical Co (ROCO:7713) has a EV-to-EBIT of 12.78 as of Sep. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Weleader Biomedical Co and its competitors. This is 21% below median its historical median of 16.15. Over the past decade, Weleader Biomedical Co's EV-to-EBIT has ranged from 12.31 to 35.91. According to the industry distribution chart, Weleader Biomedical Co ranks #167 out of 475 companies in the Medical Devices & Instruments industry, placing it in the top 35.2%.
Is Weleader Biomedical Co's EV-to-EBIT too high?
Weleader Biomedical Co's current EV-to-EBIT of 12.78 is 21% below median its 10-year median of 16.15. Over the past 10 years, this metric has ranged from a low of 12.31 to a high of 35.91. The Medical Devices & Instruments industry median EV-to-EBIT is 18.21. Weleader Biomedical Co's value of 12.78 is 29.8% below this industry median. Based on the distribution chart, Weleader Biomedical Co ranks #167 out of 475 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Weleader Biomedical Co has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Weleader Biomedical Co ranks #167 out of 475 companies for EV-to-EBIT. This puts Weleader Biomedical Co in the upper half of its industry. The industry median EV-to-EBIT is 18.21. Weleader Biomedical Co's value of 12.78 is 29.8% below this benchmark. Historically, Weleader Biomedical Co's own EV-to-EBIT has ranged from 12.31 to 35.91 over the past decade. While the company's 10-year median is 16.15 vs. the industry median of 18.21, Weleader Biomedical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.21, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Weleader Biomedical Co's current EV-to-EBIT of 12.78 is 29.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Weleader Biomedical Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Weleader Biomedical Co's current EV-to-EBIT is 12.78, which is 21% below median its own 10-year median of 16.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Weleader Biomedical Co (ROCO:7713) is currently considered Fairly Valued. The stock's GF Value™ is NT$74.30, compared to a current price of NT$73.90 — trading 0.5% below its estimated fair value. The current EV-to-EBIT is 12.78, which is 21% below median its 10-year median of 16.15 and 29.8% below the Medical Devices & Instruments industry median of 18.21. Weleader Biomedical Co's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current EV-to-EBIT is 12.78 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Weleader Biomedical Co (ROCO:7713) Overvalued in 2026?
Based on GuruFocus' analysis, Weleader Biomedical Co stock appears to be undervalued.
The current stock price of NT$73.90 is trading 0.5% below its estimated GF Value™ of NT$74.30.
GuruFocus considers Weleader Biomedical Co to be Fairly Valued.
Key valuation signals for ROCO:7713:
EV-to-EBIT: 12.78 (21% below median its 10-year median of 16.15)
GF Value™: NT$74.30 vs. price of NT$73.90 (0.5% below fair value)
Industry Position: 29.8% below the Medical Devices & Instruments median (#167 of 475)
No single metric tells the full story. See the ROCO:7713 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
69GF Score
Get the complete analysis for ROCO:7713
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7713 has been successfully added to your 
